RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

Experts Michael A. Davies, MD, PhD, and Jeffrey S. Weber, MD, PhD, review key data in melanoma presented at the 2022 Society for Melanoma Research Annual Congress, from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Jeffrey S. Weber, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: December 19, 2022 Expired: December 18, 2023

Dr Michael Davies highlights key studies presented at the 2022 Society for Melanoma Research Annual Congress in this commentary from Clinical Care Options (CCO)

Michael A. Davies, MD, PhD Released: November 17, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Download slides on selected studies from the 2022 Society for Melanoma Research Annual Congress, as reported by Clinical Care Options (CCO)